Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (16962)	3/9/1998 5:12:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I would be surprised by a SERM. Evista is a SERM and they hope that it will be a $1 Billion blockbuster. I'm not sure why they would give LGND a SERM. If LGND chooses the cash, then its $20 million (off set by stock). Most of us are fairly convinced that the drug is the IL-2 fusion protein of SRGN. A SERM would be better, but I'm not sure what it would be since LGND expects the drug to help them become profitable next year and I'm not aware of a SERM nearing approval.